- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04964479
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
A Randomized, Blind, Parallel Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Pembrolizumab Injection as a First-line Treatment on Patient With Advanced NSCLC.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Baohui Han, doctor
- Phone Number: 18930858216
- Email: 18930858216@163.com
Study Locations
-
-
-
Chongqing, China
- Not yet recruiting
- Affiliated Tumor Hospital of Chongqing University
-
Contact:
- Yongsheng Li, Doctor
- Phone Number: 17784310187
- Email: yongshengli2005@163.com
-
Chongqing, China
- Not yet recruiting
- Three Gorges Hospital of Chongqing University
-
Contact:
- Biyong Ren, Master
- Phone Number: 13896327099
- Email: biyou@sina.com
-
Guangzhou, China
- Not yet recruiting
- Southern Hospital of Southern Medical University
-
Contact:
- Laiyu Laiyu, Doctor
- Phone Number: 13632102245
- Email: Liulaiyu@126.com
-
Guangzhou, China
- Not yet recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contact:
- Minghui Wang, Doctor
- Phone Number: 13826276828
- Email: wmingh@mail.sysu.edu.cn
-
Guangzhou, China
- Not yet recruiting
- Zhujiang Hospital of Southern Medical University
-
Contact:
- Xin Chen, Doctor
- Phone Number: 13902205193
- Email: chen_xin1020@163.com
-
Tianjin, China
- Not yet recruiting
- The Fifth Central Hospital of Tianjin
-
Contact:
- Guozhong Li, Master
- Phone Number: 13662186116
- Email: 13662186116@163.com
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Not yet recruiting
- China-Japan Friendship Hospital
-
Contact:
- Meng Yang, Bachelor
- Phone Number: 18618307980
- Email: 1943826591@qq.com
-
Beijing, Beijing, China
- Not yet recruiting
- Beijing Chest Hospital, Capital Medical University
-
Contact:
- Ying Hu, Doctor
- Phone Number: 13681445657
- Email: hygzz2004@163.com
-
Beijing, Beijing, China
- Not yet recruiting
- Peking University Third Hospital
-
Contact:
- Baoshan Cao, Doctor
- Phone Number: 13641093518
- Email: caobaoshan0711@aliyun.com
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Not yet recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contact:
- Jianguo Li, Doctor
- Phone Number: 13434196973
- Email: jgli88@126.com
-
Zhangjiang, Guangdong, China, 524000
- Recruiting
- Affiliated Hospital of Guangdong Medical University
-
Contact:
- Hualin Chen, Doctor
- Phone Number: 0759-2387458
- Email: 3549509@qq.com
-
Principal Investigator:
- Hualin Chen, Doctor
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Not yet recruiting
- Shanghai Chest Hospital
-
Contact:
- Baohui Han, Doctor
- Phone Number: 021-22200000
-
Principal Investigator:
- Baohui Han, Doctor
-
Shanghai, Shanghai, China, 201900
- Not yet recruiting
- The Ninth Affiliated People's Hospital of Shanghai Jiao Tong University, School of Medicine
-
Contact:
- Bin Jiang, Doctor
- Phone Number: 86-13817606255
- Email: jiangbinwcr@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Not yet recruiting
- Tianjin Cancer Hospital
-
Contact:
- Kai Li, Doctor
- Phone Number: 18622221218
- Email: likai_fnk@163.comm
-
Tianjin, Tianjin, China
- Not yet recruiting
- General Hospital of Tianjin Medical University
-
Contact:
- Diansheng Zhong, Master
- Phone Number: 86-13821377353
- Email: zhongdsh@hotmail.com
-
Tianjin, Tianjin, China
- Not yet recruiting
- Tianjin Chest Hospital
-
Contact:
- Yuechuan Li, Bachelor
- Phone Number: 18920281127
- Email: liyuechuandoctor@127.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- According to the 8th edition of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification, the tumor node metastasis (TNM) staging of lung cancer is locally advanced (stage ⅢB/ⅢC), metastatic or recurrent ( Stage IV) NSCLC patients. (Note: Mixed tumors will be classified according to the main cell type; if there are small cell components, the subject is unqualified).
- Between the ages of 18-75 years (calculated based on the date of signing ICF); male or female; Eastern cooperative oncology group (ECOG) score 0-1; estimated survival time ≥ 3 months.
- According to the RECIST 1.1 standard, there is at least one measurable lesion. If the measurable lesion is located in the radiotherapy area, it should be clearly defined as a progressive state.
- Patients who have not received systemic anti-tumor therapy for advanced, recurrent or metastatic diseases in the past. For those who have received adjuvant chemotherapy in the past, the interval between the recurrence time and the last adjuvant chemotherapy should be at least 6 months; The interval between the end of previous radiotherapy for chest and this treatment should be more than 6 months, and the interval between palliative radiotherapy for chest and this treatment should be more than 7 days.
- Tumor tissue slices that have not undergone radiotherapy at or after the diagnosis of advanced or metastatic NSCLC must be provided. Tumor tissue samples must be archived samples or fresh samples obtained within 12 months before randomization, and the proportion of programmed death-Ligand 1(PD-L1) positive tumor cells≥ 1% (TPS ≥ 1%).
- For non-squamous NSCLC, patients with no epidermal growth factor receptor (EGFR) mutations and ALK fusions (for squamous NSCLC, patients with known EGFR mutations and anaplastic Lymphoma kinase (ALK) fusions need to be excluded, and those with unknown status are not mandatory to be tested).
The function of main organs are well and meet the following standards:
a. Routine blood examination standards (without blood transfusion or correction with hematopoietic stimulating factor drugs within 14 days before screening): i. Absolute neutrophil count (ANC) ≥1.5×109 /L; ii. Platelets ≥100×109 /L; iii. Hemoglobin ≥90 g/L. b. The blood biochemical examination shall meet the following standards: i. Total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) (Patients with Gilbert syndrome ≤ 3 × ULN); ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN. If it is accompanied by liver metastasis, ALT and AST≤5×ULN; iii. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance estimated by Cockcroft-Gault glomerular filtration formula ≥60 mL/min; iv. Serum albumin (ALB) ≥30g/L. c. Urine routine examination standard: urine routine indicates urine protein <++; if urine protein ≥++, it is necessary to confirm that the 24-hour urine protein quantitative ≤1.0 g.
d. Blood coagulation test standards: prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR)≤1.5×ULN (no anticoagulant therapy).
e. Thyroid Stimulating Hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, it can be selected.
f. Heart color Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%.
g. 12-lead ECG evaluation: QTc<450ms (male), QTc<470ms (female).
- Women of childbearing age should agree to use effective contraceptive measures during the study period and 6 months after the end of the study, and have a negative serum pregnancy test within 7 days before the study enrollment; men should agree to the study period and 6 months after the end of the study period Effective contraceptive measures must be used internally.
- The subjects voluntarily joined the study, signed the informed consent form, and had good compliance.
Exclusion Criteria:
Tumor disease and medical history:
- Brain metastases without local treatment; Note: Subjects who have previously received brain metastasis therapy and meet all the following criteria can participate in this study: i. Only supratentorial and cerebellar metastases; ii. The condition needs to be stable for ≥4 weeks and no new brain metastases or brain metastases are found Expanded imaging evidence; iii. The subject must have stopped corticosteroids/dehydrator for at least 2 weeks before starting to use the trial drug;
- There are midbrain, pons, medulla oblongata, spinal cord and meningeal metastases;
- Other malignant tumors appeared or were present within 3 years. The following two cases can be included: other malignant tumors treated by single operation have achieved 5-year Disease-free survival (DFS) in a row; The cured cervical carcinoma in situ, non melanoma skin cancer and superficial bladder tumor [ta (non-invasive tumor), tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
- Central type, cavity squamous cell carcinoma (primarily in the main bronchus and around the hilar);
- Imaging shows that the tumor invades large blood vessels or is unclearly separated from the blood vessels, or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the subsequent study(The major vessels in the chest include pulmonary aorta, left pulmonary artery, right pulmonary artery, four pulmonary veins, superior vena cava, inferior vena cava and aorta);
- Severe bone injury caused by tumor bone metastasis, including pathological fracture of weight-bearing bone and spinal cord compression that occurred within 6 months or is expected to occur in the near future(Such as spine, pelvis, femur, tibia, phalanges, calcaneus, etc.);
- Patients with serous cavity (thoracic cavity, abdominal cavity, or pericardial cavity) that require repeated drainage to relieve clinical symptoms (as determined by the investigator), or who have received drainage of serous cavity effusion for the purpose of treatment within 2 weeks before treatment.
Previous anti-tumor treatments:
- Received the treatment of proprietary Chinese medicines with anti-tumor indications specified in the NMPA approved drug instructions within 2 weeks before the start of the study treatment(Including compound cantharidin capsules, Kangai injection, Kanglaite capsule/injection, Aidi injection, brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, Huachansu capsule, etc.);
- Previously received related immunotherapy drugs for programmed death 1 (PD-1), PD-L1, cytolytic T lymphocyte-associated antigen-4 (CTLA-4), etc.;
- Previous use of anti-angiogenic drugs such as bevacizumab, anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, fruquintinib, etc.;
- Patients who have been vaccinated with immunomodulatory drugs within 30 days before starting treatment(Such as interleukin-2, thymosin, lentinan, etc.);
- Failure to recover from the toxicity and/or complications of previous interventions to CTCAE ≤1, except for hair loss and peripheral neuropathy ≤2;
Combined diseases and medical history:
a. Liver cirrhosis, active hepatitis*;(Note: active hepatitis (hepatitis B reference: HBV-DNA > 1*103 copy /mL or > 2000IU/mL) when HBsAg is positive. Hepatitis C reference: HCV antibody is positive, and HCV titer detection value exceeds the upper limit of normal value); b. Renal abnormalities: i.Renal failure requires hemodialysis or peritoneal dialysis; ii.Previous or existing nephrotic syndrome, chronic nephritis. c. Cardiovascular and cerebrovascular abnormalities: i.Patients with previous or present heart failure, degree II or above heart block: ii.Myocardial infarction or unstable angina, supraventricular or ventricular arrhythmia with clinical significance need treatment or intervention; iii.Vascular embolism and cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage and cerebral infarction) occurred within 9 months( Prophylactic use of anticoagulant therapy is allowed for patients with thrombotic tendency or undergoing anticoagulant therapy.) iv.After more than two kinds of drug treatment, blood pressure control is still not ideal (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg).
d. Gastrointestinal abnormalities: i.Inability to take medications (such as inability to swallow, intestinal obstruction, etc.); ii.A history of malabsorption syndrome or other diseases that interfere with gastrointestinal absorption; iii.Received treatment for active peptic ulcer in the past 6 months; iv.Despite the maximum medical treatment, chronic diarrhea of grade 2 and above continues to occur; v.Other conditions determined by the researcher that may cause gastrointestinal bleeding and perforation.
e. History of immunodeficiency: i.Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases; ii.Active autoimmune disease or history of autoimmune disease, including but not limited to Crohn's disease, ulcerative colitis, autoimmune hepatitis/enteritis/vasculitis/nephritis, etc.
iii.Prepare to undergo or have previously received an organ transplant; iv.Patients who require systemic or topical immunosuppressive therapy to achieve immunosuppressive purposes and need to continue to use them within two weeks before randomization (except for glucocorticoid daily dose <10 mg prednisone or other equivalent hormones).
Note: Hormone replacement therapy (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered as systemic therapy and allowed to be used.
f. Bleeding risk: i.Suffered from bleeding or coagulopathy within 28 days before the start of treatment or was using warfarin, aspirin and other antiplatelet agglutination drugs (except for aspirin ≤100 mg/d preventive drugs); ii.Had hemoptysis >2.5 mL/day in 28 days before the start of treatment; iii.Regardless of the severity, patients with any history of bleeding or coagulopathy; iv.Received major surgical treatment, open biopsy, etc. within 28 days before the start of the study treatment; v.Long-term unhealed wounds or fractures, except for pathological fractures; g. Poor control of type I diabetes or II diabetes (fasting blood glucose (FBG)> 10mmol/L); h. Severe infections within 4 weeks before the start of study treatment, including but not limited to hospitalization due to bacteremia, severe pneumonia, or other severe infections; subjects with ≥ grade 2 active infections within 4 weeks before the start of study treatment Or fever of unknown cause occurred during the screening period and before the first administration>38.0℃; i. Past or existing pneumoconiosis, interstitial pneumonia, (non-infectious) pneumonia that requires adrenal corticosteroid therapy, currently suffering from other types of pneumonia ≥2, or lung function tests confirmed severely impaired lung function (Forced Expiratory Volume in the first second (FEV1) or diffusing capacity of lung for carbon monoxide(DLCO) or DLCO per alveolar volume (DLCO /VA) accounts for the expected value %<40%) and other objective evidence; j. Patients with active tuberculosis within 1 year before enrollment; subjects with a history of active pulmonary tuberculosis infection 1 year ago must provide clear evidence of cure before enrollment; if tuberculosis is suspected during the screening period, chest radiographs and sputum must be passed Enter the group only after the liquid and clinical symptoms are eliminated; k. Allergies, or a history of severe allergies in the past, or severe hypersensitivity reactions after receiving other monoclonal antibody treatments, or known allergies to the ingredients of the study drug excipients; l. Previous history of severe mental disorders; m. People with a history of drug abuse, alcohol or drug abuse;
- The end of the previous clinical study (last dose) is less than 4 weeks or the study drug's 5 half-lives, whichever is shorter.
- Live attenuated vaccine vaccination history within 28 days before randomization or planned live attenuated vaccination during the study period. Seasonal influenza vaccine for injection is usually an inactivated virus vaccine and is allowed to be vaccinated during the study period.
- Female patients during pregnancy or lactation.
- According to the investigator's point of view, it may increase the risks associated with participating in the study, or other severe, acute or chronic medical diseases or laboratory abnormalities that may interfere with the interpretation of the study results, or other reasons that are not suitable for participating in this clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQB2450 injection + Anlotinib Hydrochloride capsules
TQB2450 injection: once every 3 weeks, 1200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur. Anlotinib Hydrochloride capsules: once a day,12mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur. |
1200mg injection once every 3 week
12mg capsule once daily
|
Active Comparator: Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules
Pembrolizumab injection: once every 3 weeks, 200mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur. Placebo of Anlotinib hydrochloride capsules:once a day, 0mg each time, oral administration before breakfast. Continuous administration for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment. Until the disease progression or unbearable adverse events occur. |
200mg injection once every 3 week
Placebo capsule once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)
Time Frame: Baseline to up to two years
|
The period from the first use of the drug to disease progression or death (whichever occurs first)
|
Baseline to up to two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Baseline to up to two years
|
The preriod from the first use of the drug to death from all causes.
For subjects who are still alive at the last follow-up, the OS will be counted as data censored based on the last follow-up.
For subjects who are lost follow-up, the OS will be counted as data censored based on the last confirmed survival time before being lost to follow-up.
|
Baseline to up to two years
|
Disease PFS evaluated by investigators
Time Frame: Baseline to up to two years
|
The period from the first use of the drug to disease progression or death (whichever occurs first)
|
Baseline to up to two years
|
Objective response rate (ORR) evaluated by investigators
Time Frame: Baseline to up to two years
|
According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST, the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation.
It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.
|
Baseline to up to two years
|
Disease Control Rate (DCR)
Time Frame: Baseline to up to two years
|
Proportion of subjects whose tumors shrink or remain stable for a certain period, including CR, PR and stable disease(SD)
|
Baseline to up to two years
|
Duration of response (DOR)
Time Frame: Baseline to up to two years
|
The period from firstly-recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurs first) .
|
Baseline to up to two years
|
DOR rate (≥ 6 months) (the proportion of subjects with DOR ≥ 6 months)
Time Frame: Baseline to up to two years
|
The proportion of subjects reaching 6 months from firstly- recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurred first) .
|
Baseline to up to two years
|
OS rate of 12 months
Time Frame: Baseline to up to two years
|
The proportion of subjects who survive for 12 months after the first dose
|
Baseline to up to two years
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs),as well as abnormal laboratory examination indicators.
Time Frame: Baseline to up to two years
|
The proportion of AEs and SAEs recorded afte signing the informed consent form(ICF).
|
Baseline to up to two years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQB2450-III-09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on TQB2450 injection
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Xianhai MaoChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHepatocellular Carcinoma | Adjuvant TherapyChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownTriple Negative Breast Cancer (TNBC)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Solid TumorChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Biliary Adenocarcinoma/Hepatocellular CarcinomaChina
-
Peking UniversityNot yet recruiting
-
Jinming YuRecruitingLimited Stage Small Cell Lung Cancer | Not Progressed After First-line ChemoradiotherapyChina
-
Peking UniversityUnknownPatients With Digestive System Tumors Resistant to PD-1 Inhibitors
-
Cancer Institute and Hospital, Chinese Academy...RecruitingPatients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or MetastasiChina